Close menu




September 16th, 2025 | 07:25 CEST

Broadcom, NetraMark, Adobe – The AI wave continues to roll inexorably forward

  • Biotechnology
  • Biotech
  • AI
  • Software
  • Technology
Photo credits: pixabay.com

Artificial intelligence is more than just hype; it is becoming the central driver of innovation in our time. Whether in industry, medicine, mobility, or finance, this technology is changing processes, increasing efficiency and creating new business models in almost all sectors. Companies that embrace AI early on secure clear competitive advantages. At the same time, a future market with enormous potential is opening up for investors. However, despite the rosy outlook, stock picking is also required here, as many companies are significantly overvalued.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BROADCOM INC. DL-_001 | US11135F1012 , NETRAMARK HOLDINGS INC | CA64119M1059 , ADOBE INC. | US00724F1012

Table of contents:


    Broadcom – Steep rise following AI forecast

    The figures and forecasts of peer group company Oracle regarding the future of AI helped the US tech giant gain over 17% to a new all-time high of USD 359.87. This represents a whopping increase of around 150% over a 12-month period.

    After the hype surrounding AI training, the focus is now shifting to the next phase, known as "inferencing," which involves the use of trained models in real time. And this is precisely where the market sees the next billion-dollar opportunity. While NVIDIA and AMD remain the dominant names in AI, Broadcom is emerging as a quiet winner. The Company supplies specialized chips, known as ASICs, which are optimized for inferencing: they are cheaper, more efficient, and ideally suited for the requirements of large cloud providers.

    Stephanie Link, Chief Investment Strategist at Hightower Advisors, summed it up: "Inference is the new growth engine, and Broadcom is leading the field." There was a strong tailwind last week from Oracle, which is seeing exploding demand for inference performance. Oracle CEO Larry Ellison speaks of a "much bigger market than training" and forecasts USD 144 billion in cloud revenue by 2030.

    Broadcom scores not only with hardware, but also with a rapidly growing software business, which now contributes 41% of its revenue.

    NetraMark: AI as a game changer in clinical research

    Developing new drugs is expensive and risky, especially when active ingredients fail in late-stage trials. This is precisely where NetraMark Holdings comes in. With its NetraAI platform, the Canadian company uses generative AI and machine learning to identify patterns in patient data that typically remain hidden with traditional methods. Instead of relying solely on historical data, the technology analyzes individual data sets from ongoing and completed studies. Thousands of data points are generated per patient, which NetraAI transforms into actionable insights. The goal: better study designs, lower dropout rates, and development times shortened by up to 30%.

    An important step toward validation is regulatory recognition by the US Food and Drug Administration (FDA). NetraMark has been granted a Critical Path Innovation Meeting (CPIM) to clarify the regulatory classification of its technology. A positive response would send a strong signal to the market.

    The Company is also gaining momentum commercially. Through a strategic alliance with Worldwide Clinical Trials (WCT), NetraAI will be used in Phase 2 studies for neurological and oncological drugs in the future. Additionally, NetraMark has established partnerships with the National Institute of Mental Health and a leading pharmaceutical company. A recent milestone is a contract with Asklepion Pharmaceuticals, under which NetraAI will be used in a Phase III trial investigating the efficacy of L-citrulline in children with congenital heart defects.

    In addition to its core analytics capabilities, NetraMark is developing additional tools, such as for real-time review of patient profiles or monitoring the performance of individual study centers. The addressable market volume for clinical trial support is estimated at USD 47 billion. By comparison, NetraMark remains modestly valued at just CAD 127.61 million, highlighting its significant upside potential.

    Adobe – Better than expected

    US software giant Adobe also benefited from the booming AI business and surprised with better-than-expected third-quarter figures. Although Adobe shares rose by around 2.5% in after-hours trading, they are still down more than 20% since the beginning of the year.

    The outlook is particularly optimistic. For the current quarter, Adobe expects earnings per share of between USD 5.35 and USD 5.40, exceeding market expectations of USD 5.34. Revenue is expected to reach USD 6.08 to USD 6.13 billion, also slightly above analysts' estimates.

    The focus is on the Digital Media segment, which includes Photoshop, Illustrator, and others. The Company now expects full-year revenue growth of 11.3%, slightly above the previous forecast. Revenue for the entire third quarter was USD 5.99 billion, up 11% from the same period last year, while adjusted earnings were USD 5.31 per share, beating the forecast of USD 5.18 per share.

    The number one growth driver is the integration of artificial intelligence into Adobe's product range. CEO Shantanu Narayen emphasized that annualized revenue from AI-based features already exceeds USD 5 billion, a jump from USD 3.5 billion last year.


    Broadcom benefited from Oracle's forecast for the AI business. Adobe exceeded both its revenue and earnings forecasts. NetraMark could emerge as a game changer in clinical research with its AI-powered platform.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Jens Castner on November 19th, 2026 | 05:33 CET

    Gold diggers and shovel sellers: SpaceX, Amazon and HPQ Silicon in the race for internet from space

    • Spaceflight
    • Satellites
    • Batteries
    • Technology
    • Data centres
    • Rechargeable batteries
    • SpaceX
    • Amazon
    • HPQ Silicon

    Created and published on behalf of HPQ Silicon

    A spacecraft lands in the launch tower's mechanical arms, while another rocket carrying 40 satellites crashes into the sea. Rarely has the race for internet dominance in space received so much media attention as it did last weekend. SpaceX and Amazon are investing billions in orbital networks and have a combined market value of around USD 4.7 trillion. But, as in every gold rush, it is primarily the shovel sellers who stand to benefit most. HPQ Silicon aims to take on that role. The little-known Canadian company has a stock market value that is only a fraction of what the two giants are worth.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read